Prostate Cancer | Clinical

Adding 177Lu-PSMA-617 to Standard of Care Significantly Prolongs Survival in mCRPC

July 20, 2021

In patients with progressive prostate-specific membrane antigen positive metastatic castration-resistant prostate cancer receiving treatment in the phase 3 VISION trial, the addition of the targeted radioligand therapy 177Lu-PSMA-617 to standard of care led to a nearly 40% reduction in the risk of death versus SOC alone.

Lymph Node Invasion in Prostate Cancer May Be Highly Predictable With Ga-68 PSMA PET

July 15, 2021

A study has shown that Ga-68 PSMA PET imaging predicted lymph node invasion in patients with prostate cancer at a higher specificity and higher positive predictive value compared with 3 nomograms at predicting lymph node invasion.

Safety Profile of LuPSMA Therapy in mCRPC

July 07, 2021

Dr Andrew J. Armstrong reviews the safety of LuPSMA therapy as compared to cabazitaxel as seen in the phase 2 TheraP trial and comments on sequencing strategies for patients with metastatic castration-resistant prostate cancer.